J. Scott Garland sold $607k of ELVN
director at Enliven Therapeutics, Inc.. 13,000 shares at an average of $46.67, traded Oct 1, 2026, filed Oct 5, 2026.
Score components
- +15RoleDirector
- +19Trade size$607k at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001533228-26-000009, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 1, 2026 | MOption exercise Common Stock | +13,000 | $15.47 | $201k | 13,000 | 7 d ago |
| Oct 1, 2026 | SOpen-market sale Common Stock | -13,000 | $46.67 | $607k | 0 | 7 d ago |
| Oct 1, 2026 | MOption exercise Stock Option (right to buy)derivative | -13,000 | $0.00 | $0 | 46,372 | 7 d ago |
Related signals
Other insiders at Enliven Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 13Weak | Enliven Therapeutics, Inc. | Helen Louise Collins CHIEF MEDICAL OFFICER | $252k 5,000 shares | -17% | |
| 21Weak | Enliven Therapeutics, Inc. | Benjamin Hohl CHIEF FINANCIAL OFFICER | $303k 6,018 shares | -14% | |
| 12Weak | Enliven Therapeutics, Inc. | Joseph P Lyssikatos CHIEF SCIENTIFIC OFFICER | $81k 4,000 shares | -0% | |
| 21Weak | Enliven Therapeutics, Inc. | Samuel Kintz PRESIDENT AND CEO | $74k 3,700 shares | -0% | |
| 8Weak | Enliven Therapeutics, Inc. | Joseph P Lyssikatos CHIEF SCIENTIFIC OFFICER | $30k 1,500 shares | -0% | |
| 20Weak | Enliven Therapeutics, Inc. | Samuel Kintz PRESIDENT AND CEO | $56k 2,800 shares | -0% | |
| 21Weak | Enliven Therapeutics, Inc. | Joseph P Lyssikatos CHIEF SCIENTIFIC OFFICER | $136k 7,000 shares | -1% | |
| 30Weak | Enliven Therapeutics, Inc. | Samuel Kintz PRESIDENT AND CEO | $116k 6,000 shares | -1% | |
| 26Weak | Enliven Therapeutics, Inc. | Anish Patel CHIEF OPERATING OFFICER | $135k 6,667 shares | -2% | |
| 15Weak | Enliven Therapeutics, Inc. | Benjamin Hohl CHIEF FINANCIAL OFFICER | $67k 3,250 shares | -12% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.